Posted by Michael Wonder on 14 Aug 2024
Galderma receives US FDA approval for Nemluvio (nemolizumab) for adult patients living with prurigo nodularis
13 August 2024 - The US FDA granted Nemluvio priority review for the treatment of prurigo nodularis in February 2024, following its breakthrough therapy designation in 2019.
Galderma today announced that the US FDA has approved Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis.
